A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects

INTRODUCTION: Pyroglutamate-amyloid-β (pE-Aβ) peptides are major components of Aβ-oligomers and Aβ-plaques, which are regarded as key culprits of Alzheimer's disease (AD) pathology. PQ912 is a competitive inhibitor of the enzyme glutaminyl cyclase (QC), essential for the formation of pE-Aβ pept...

Descripción completa

Detalles Bibliográficos
Autores principales: Lues, Inge, Weber, Frank, Meyer, Antje, Bühring, Uli, Hoffmann, Torsten, Kühn-Wache, Kerstin, Manhart, Susanne, Heiser, Ulrich, Pokorny, Rolf, Chiesa, Joseph, Glund, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975062/
https://www.ncbi.nlm.nih.gov/pubmed/29854937
http://dx.doi.org/10.1016/j.trci.2015.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975062/
https://www.ncbi.nlm.nih.gov/pubmed/29854937
http://dx.doi.org/10.1016/j.trci.2015.08.002

Ejemplares similares